Novartis

Haberler

Reuters - 2 gün önce

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.

Reuters - 2 gün önce

Companies ask US judiciary group to force lawsuit funding disclosures

Reuters - 2 gün önce

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou

Reuters - 2 gün önce

US office real estate market shows signs of bottoming after big discount sales

ANALYSIS-US office real estate market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market Adds refinancing stats in paragraph 16, updates headline By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.

Reuters - 3 gün önce

US office market shows signs of bottoming after big discount sales

ANALYSIS-US office market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.

Reuters - 3 gün önce

Swiss stocks - Factors to watch on October 3

Swiss stocks - Factors to watch on October 3 ZURICH/GDANSK, Oct 3(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS Sika AG SIKA.S holds its Capital Markets Day. ANALYSTS' VIEWS NOVARTIS AG NOVN.S - JEFFERIES RAISES TARGET PRICE TO $124 FROM $123 ECONOMY Swiss September inflation data due at 0630 GMT.

Reuters - 1 hafta önce

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.

Reuters - 1 hafta önce

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Reuters - 1 hafta önce

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Reuters - 2 hafta önce

Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai

BRIEF-Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai Sept 24 (Reuters) - Novartis AG NOVN.S : GENERATE:BIOMEDICINES: ANNOUNCES MULTI-TARGET COLLABORATION WITH NOVARTIS TO DISCOVER & DEVELOP PROTEIN THERAPEUTICS WITH GENERATIVE AI GENERATE:BIOMEDICINES - POTENTIA

Reuters - 2 hafta önce

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

Reuters - 2 hafta önce

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.

Reuters - 3 hafta önce

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit

Reuters - 3 hafta önce

Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients

BRIEF-Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients Sept 18 (Reuters) - Novartis AG NOVN.S : NEW NOVARTIS DATA IN RELAPSING MS REINFORCE BENEFITS OF KESIMPTA® FOR FIRST-LINE AND SWITCH PATIENTS NEARLY 90% OF FIRST-LINE KESIMPTA PATIENTS HAD NO DISABILITY PROGRESSION INDEPENDENT OF RELAPSE ACTI

Reuters - 3 hafta önce

Swiss stocks - Factors to watch on September 18

Swiss stocks - Factors to watch on September 18 ZURICH/GDANSK, Sept 18 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: MEYER BURGER TECHNOLOGY AG MBTN.S The company said it has planned the streamlining of its group structure and the reduction of its workforce. NOVARTIS AG NOVN.S FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer.

Reuters - 3 hafta önce

Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Sept 17 (Reuters) - Novartis AG NOVN.S : FDA APPROVES NOVARTIS KISQALI® TO REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nGNEVXqGz Further company coverage: NOVN.S

Reuters - 3 hafta önce

Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer

BRIEF-Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer Novartis AG NOVN.S : : NOVARTIS KISQALI® SHOWS DEEPENING BENEFIT IN NEW ANALYSIS, REDUCING RISK OF RECURRENCE BY 28.5% IN A BROAD POPULATION OF PATIENTS WITH EARLY BREAST CANCER

Reuters - 3 hafta önce

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 3 hafta önce

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 3 hafta önce

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Novartis

Haberler

Şartlar

Popüler varlıklar

XM canlı destek